Evidence map›Paper›PMID 40421081›Full record

ReviewFrontiers in oncology2025

Exploring the complex role of the Eph/Ephrin signaling in oral and maxillofacial cancers.

Reydson Alcides de Lima-Souza, Moisés Willian Aparecido Gonçalves, Raisa Sales de Sá, Luccas Lavareze, João Figueira Scarini, Talita de Carvalho Kimura, Fernanda Cristina Poscai Ribeiro, Albina Altemani, Fernanda Viviane Mariano, Gary Chris Fillmore and 1 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Reydson Alcides de Lima-Souza *Department of Pathology, School of Medical Sciences, University of Campinas (FCM/UNICAMP), Campinas, São Paulo, Brazil.
Moisés Willian Aparecido Gonçalves *Department of Pathology, School of Medical Sciences, University of Campinas (FCM/UNICAMP), Campinas, São Paulo, Brazil.
Raisa Sales de Sá *Department of Oral Diagnosis, Piracicaba School of Dentistry, University of Campinas (FOP/UNICAMP), Piracicaba, São Paulo, Brazil.
Luccas LavarezeDepartment of Pathology, School of Medical Sciences, University of Campinas (FCM/UNICAMP), Campinas, São Paulo, Brazil.
João Figueira ScariniDepartment of Pathology, School of Medical Sciences, University of Campinas (FCM/UNICAMP), Campinas, São Paulo, Brazil.
Talita de Carvalho KimuraDepartment of Pathology, School of Medical Sciences, University of Campinas (FCM/UNICAMP), Campinas, São Paulo, Brazil.
Fernanda Cristina Poscai RibeiroDepartment of Internal Medicine, University of Western São Paulo (UNOESTE), Guarujá, São Paulo, Brazil.
Albina AltemaniDepartment of Pathology, School of Medical Sciences, University of Campinas (FCM/UNICAMP), Campinas, São Paulo, Brazil.
Fernanda Viviane MarianoDepartment of Pathology, School of Medical Sciences, University of Campinas (FCM/UNICAMP), Campinas, São Paulo, Brazil.
Gary Chris Fillmore *Biorepository and Molecular Pathology, Huntsman Cancer Institute, University of Utah (UU), Salt Lake City, UT, United States.
Erika Said Abu Egal *Department of Pathology, School of Medical Sciences, University of Campinas (FCM/UNICAMP), Campinas, São Paulo, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Eph (erythropoietin-producing hepatocellular carcinoma) receptor family represents the largest subgroup within the tyrosine kinase receptor family and is recognized for its critical role in regulating the growth, migration, and survival of both normal and malignant cells. The Eph/ephrin signaling has an ambiguous role in squamous cell carcinomas of the oral region, playing both a suppressive and oncogenic role. In salivary gland cancers, the results are reserved, although they suggest that some molecules are associated with a worse prognosis for patients. This review offers a comprehensive summary of the existing literature, underscoring the evidence that supports the involvement of the Eph/ephrin signaling in oral and maxillofacial cancers. Additionally, we examine molecular discoveries that may present promising therapeutic targets for these malignancies.

Indexed as

Ephephrinoral squamous cell carcinomasalivary gland cancerstarget therapy

Identifiers

PMID40421081
PMCPMC12104300

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.